• / Free eNewsletters & Magazine
  • / My Account
Home>Funds>Central Securities

Central Securities

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Elekta to continue to help bring radiation treatment to developing countries with nonprofit organization Radiating Hope

    Elekta to continue to help bring radiation treatment to developing countries with nonprofit organization Radiating Hope

  2. Medivir: Updated Interim Phase IIa Data Demonstrate That the Combination of Simeprevir, Odalasvir and AL-335 Has a High Level of Efficacy in HCV Patients

    Medivir: Updated Interim Phase IIa Data Demonstrate That the Combination of Simeprevir, Odalasvir and AL-335 Has a High Level of Efficacy in HCV Patients

  3. Elekta: First patient in Switzerland treated with Elekta’s Leksell Gamma Knife Icon

    Elekta: First patient in Switzerland treated with Elekta’s Leksell Gamma Knife Icon

  4. NICE Presents ‘Experiences Persona-lized’ Roadshow in Six North American Cities

    NICE Presents ‘Experiences Persona-lized’ Roadshow in Six North American Cities

  5. AAK AB: Invitation to Capital Market Day

    AAK AB: Invitation to Capital Market Day

  6. Kungl. Vetenskapsakademien: Announcements of the Nobel Prizes in Physics, Chemistry and the Prize in Economic Sciences 2016

    Kungl. Vetenskapsakademien: Announcements of the Nobel Prizes in Physics, Chemistry and the Prize in Economic Sciences 2016

  7. Sectra: Sectra’s three-month interim report 2016/2017: Multiyear managed-services agreements contribute to Sectra’s positive performance

    Sectra: Sectra’s three-month interim report 2016/2017: Multiyear managed-services agreements contribute to Sectra’s positive performance

  8. AGM 2017: Election Committee of Castellum AB

    AGM 2017: Election Committee of Castellum AB

  9. Swedish Match is contemplating issuance of public note and a tender of part of outstanding note

    Swedish Match is contemplating issuance of public note and a tender of part of outstanding note

  10. Medivir: Interim Results from Phase IIa Trial Evaluating Triple Combination Including Simeprevir Demonstrates High Level of Efficacy in HCV Patients

    Medivir: Interim Results from Phase IIa Trial Evaluating Triple Combination Including Simeprevir Demonstrates High Level of Efficacy in HCV Patients

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.